SummitTX Capital’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-96,018
Closed -$5.45M – 1108
2026
Q2
$5.45M Buy
+96,018
New +$4.26M 0.14% 173
2025
Q2
– Sell
-112,040
Closed -$2.01M – 1011
2025
Q1
$2.01M Buy
+112,040
New +$2.27M 0.09% 249

Other funds holding TVTX

SummitTX Capital's TVTX Position: Q3 2026 in Review

SummitTX Capital sold out of Travere Therapeutics (TVTX) in Q3 2026, closing a stake of 96,018 shares — an estimated $5.45M sold.

SummitTX Capital first reported a position in TVTX in Q1 2025 and held it in 2 quarters. The position peaked at $5.45M in Q2 2026. 345 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • SummitTX Capital reported no remaining Travere Therapeutics position as of Q3 2026 after selling out during the quarter.
  • SummitTX Capital sold 96,018 Travere Therapeutics shares in Q3 2026, an estimated $5.45M.
  • SummitTX Capital first reported a position in Travere Therapeutics in Q1 2025 and held it in 2 quarters.
  • SummitTX Capital's Travere Therapeutics position peaked at $5.45M in Q2 2026.
  • 345 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on SummitTX Capital's 13F filing for Q3 2026, filed 16 Nov 2026.